Ascidian Therapeutics
Sarah Fashena has held various positions in the field of intellectual property strategy, with a focus on biotechnology and pharmaceuticals. Sarah is currently the VP of Intellectual Property Strategy at Ascidian Therapeutics and has experience working at Entrinsic Health Solutions, Greenberg Traurig, LLP, Klauber & Jackson, and DANN, Dorfman, Herrell and Skillman. Prior to their corporate roles, Sarah was a Senior Post-doctoral Fellow at Fox Chase Cancer Center and a Postdoctoral Fellow at Caltech. Sarah holds a Ph.D. in Biology from Yale University and a B.A. in Biology from Purchase College, SUNY.
This person is not in the org chart
This person is not in any offices
Ascidian Therapeutics
2 followers
Gene therapy is entering a new era as the field moves forward. But current technologies cannot overcome the challenges of many diseases. Ascidian’s unique approach aims to unlock these doors and enable treatment for millions of patients worldwide.